CB 103

Drug Profile

CB 103

Alternative Names: CB-103

Latest Information Update: 12 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Cellestia Biotech
  • Class
  • Mechanism of Action Notch signalling pathway inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Haematological malignancies; Solid tumours
  • Preclinical Leukaemia; Lymphoma

Most Recent Events

  • 12 Sep 2017 Preclincal data in Solid tumours and Haematological malignancies presented at the 42nd European Society for Medical Oncology Congress (ESMO-2017)
  • 11 Aug 2017 Phase-I/II clinical trials in Haematological malignancies in Spain (PO) (EudraCT2017-001491-35)
  • 11 Aug 2017 Phase-I/II clinical trials in Solid tumours (Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) in Spain (PO) (EudraCT2017-001491-35)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top